IMAN NABILAH ABD RAHIM

Dr. IMAN NABILAH ABD RAHIM

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2022 in Malaysian Journal of Medical Sciences
Verified
Journal Article
Open access
IMAN NABILAH ABD RAHIMIMAN NABILAH ABD RAHIM
IMAN NABILAH ABD RAHIM
NKNoor Alicezah Mohd Kasim
Noor Alicezah Mohd Kasim
MIMohamad Rodi Isa
Mohamad Rodi Isa
HNHapizah Nawawi
Hapizah Nawawi
Saffron is widely used in traditional medicine to treat various medical disorders, including hyperlipidaemia. This study aims to systematically review the effects of saffron extract (SE) on lipid profile in in vivo studies. A strategic literature search was done following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The Scopus, PubMed (MEDLINE) and Web of Science databases and hand-searching methods were utilised to identify studies published up to January 2020 that reported the effects of SE on lipid profile in a hyperlipidaemic experimental animal model. A total of six articles met the inclusion criteria. The methods of extraction were aqueous (n = 4), ethanolic (n = 1) and hydroalcoholic (n = 1) extracts. Five doses of SE ranging from 10 mg/kg to 100 mg/kg were administered to rats and hamsters, with a duration ranging from 10 days to 8 weeks. SE at doses of 40 mg/kg/day and 80 mg/kg/day significantly decreased the levels of total cholesterol (21.4%–35.4%), low-density lipoproteins (38.7%–50.0%) and triglycerides (TGs) (29.1%–45.0%) and markedly increased the level of high- density lipoproteins (36.6%–65%) in the treated group compared to the untreated group with a minimum 3-week intervention duration (P < 0.05). This systematic review demonstrated that SE exhibits hypolipidaemic effects compared to a placebo. SE has almost the same ability to reduce cholesterol levels as the standard therapy.

23 May 2025 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
IMAN NABILAH ABD RAHIMIMAN NABILAH ABD RAHIM
IMAN NABILAH ABD RAHIM
EOEffat Omar
Effat Omar
SMSuhaila Abd Muid
Suhaila Abd Muid
NANOOR ALICEZAH
NOOR ALICEZAH
Saffron, the dried stigma of the flower Crocus sativus L., has been shown to have therapeutic effects on cardiovascular diseases. Several studies have explored the impact of saffron on atherosclerosis. However, the mechanism underlying the plaque-stabilizing and antiatherosclerotic effects of saffron has not been widely studied. Therefore, this study aimed to investigate the mechanism of the antiatherosclerotic and plaque-stabilizing effects of saffron ethanolic extract in experimentally induced atherosclerotic rabbits. New Zealand White rabbits were fed a 1% high-cholesterol diet (HCD) for 8 weeks to induce established atherosclerosis. The rabbits were then treated with 50 or 100 mg/kg/day saffron ethanolic extract (SAF), simvastatin (2.5 mg/kg/day) or placebo for another 8 weeks. Body weight, lipid profile, percentage of atherosclerotic lesions, immunohistochemical analysis, and quantitative real-time polymerase chain reaction were performed at baseline, after high-cholesterol diet feeding, and after the intervention. The results showed that SAF had no significant effect on body weight. However, treatment with both doses of SAF markedly attenuated the levels of low-density lipoprotein (LDL) and total cholesterol (TC) in atherosclerotic rabbits. Higher doses of SAF markedly reduced atherosclerotic lesions in rabbit aortas. Additionally, SAF suppressed the tissue and gene expression of adhesion molecules and pro-inflammatory biomarkers in the aorta. SAF also reduced MMP-9 tissue expression in the aortas of atherosclerotic rabbits, thereby increasing plaque stability. Our findings suggest that saffron ethanolic extract exhibits therapeutic potential in rabbits with HCD-induced atherosclerosis. This effect may be associated with the modulation of inflammatory pathways, leading to reduced expression of pro-inflammatory cytokines, endothelial activation markers, and matrix metalloproteinases. The observed reduction in vascular inflammation and endothelial activation may contribute to improved lipid profiles, decreased atherosclerotic lesion severity, and enhanced plaque stability. While these findings highlight the potential of saffron ethanolic extract as an adjunctive treatment for atherosclerosis, further studies are warranted to clarify its direct effects on lipid metabolism and underlying molecular mechanisms. Not applicable.

11 January 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IMAN NABILAH ABD RAHIMIMAN NABILAH ABD RAHIM
IMAN NABILAH ABD RAHIM
NANOOR ALICEZAH
NOOR ALICEZAH
EOEffat Omar
Effat Omar
SMSuhaila Abdul Muid
Suhaila Abdul Muid
HNHapizah Nawawi
Hapizah Nawawi
Previous research has shown that natural medications pose health risks, especially in subjects with comorbidities. This study aimed to evaluate the safety of saffron ethanolic extract (SEE) administration in early and established atherosclerotic rabbits. Rabbits were given a high-cholesterol diet (HCD) for 4 and 8 weeks to induce early and established atherosclerosis respectively, and then they were treated with 50 and 100 mg/kg/day SEE. The body weight of the animals was recorded. Blood samples were collected at baseline, pre-treatment, and post-treatment for hematological studies, lipid profiles, and biochemical profiles. Tissue specimens of the vital organs were subjected to histological examination. The above parameters were significantly altered post-intervention with 4 and 8 weeks of HCD. No significant differences in body weight were observed in all the groups post-treatment with 50 and 100mg/kg of SEE compared to pre-treatment. However, low-density lipoprotein cholesterol, total cholesterol, serum urea, and glucose significantly decreased post-treatment with 50 and 100mg/kg/day SEE compared to pre-treatment in early and established atherosclerosis groups. Hematological parameters that were affected post-intervention with HCD returned to their baseline values post-treatment with 50 and 100mg/kg/day SEE. There was a significant improvement in the vital organs post-treatment with 50 and 100mg/kg SEE. SEE can safely be administered without causing harmful effects on the hematological, biochemical profiles, and vital organs. Notably, SEE exerts hypolipidemic and hypoglycemic effects on atherosclerotic conditions. Further clinical trials are warranted to ensure the safety of saffron administration in patients with atherosclerosis-related diseases.

14 January 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YSYasmin Mohd Zainal Abidin Shukri
Yasmin Mohd Zainal Abidin Shukri
IMAN NABILAH ABD RAHIMIMAN NABILAH ABD RAHIM
IMAN NABILAH ABD RAHIM
NNNurul Alimah Abdul Nasir
Nurul Alimah Abdul Nasir
COChe Puteh Osman
Che Puteh Osman
NANOOR ALICEZAH
NOOR ALICEZAH
Cataracts are significant causes of blindness, closely linked to prolonged hypercholesterolemia. While saffron has the potential for eye health, its effects on lens lesions remain understudied. This study aimed to investigate the effect of saffron on the lens changes in atherosclerotic-induced New Zealand white rabbits (NZWR). Thirty-five NZWRs were subjected to four to eight weeks of high-cholesterol diet to induce atherosclerosis, resulting in cataractous lens changes. The rabbits were categorised randomly into three groups: normal diet group, pre-treated group and treated group. The pre-treated group was divided into early atherosclerosis(HC4) and established atherosclerosis (HC8). The saffron-treated group was fed with the HCD diet followed by saffron treatment of 50mg/kg/day (TG450, TG840) and 100mg/kg/day (TG4100, TG8100) of saffron ethanolic extract (SEE) respectively. The normal diet group was given a normal diet over the 8 weeks. After completing the 16-week experimental protocol, the NZWR were euthanized, and their lenses were extracted for histopathological evaluation. The pre-treated group exhibited cataractous lens changes of grade 2, characterized by increased homogenisation, swollen lens fibers, and intracellular vacuolisation. Interestingly, these cataract changes showed a positive trend from grade 2 to grade 1 post-treatment with SEE. In the saffron-treated group, vacuoles and pinkish homogenised areas were reduced. Additionally, a uniform layer of anterior epithelium and decreased non-swollen lens fibers indicated significant cataract lesion improvement. The normal diet group displayed minimal to zero cataractous changes (Grade 0). HPLC analysis demonstrated the presence of crocin, crocetin, and picocrocin in the saffron ethanolic extract, with peak absorptions at 440nm (12.817min), 440nm (1.620min), and 254nm (6.553min) respectively. The phytochemical screening of saffron ethanolic extract was conducted and showed the presence of phytochemical compounds including saponins, flavonoids, tannins, and steroids. The positive effects on lenses in the TG groups could be due to crocin and crocetin, bioactive components of saffron, and its phytochemical compounds. This study highlights saffron’s potential in managing cataract-induced conditions, emphasizing the importance of further research for its full therapeutic potential in cataract management.

31 January 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
NANOOR ALICEZAH
NOOR ALICEZAH
NBNurul Ain Abu Bakar
Nurul Ain Abu Bakar
RARadzi Ahmad
Radzi Ahmad
IMAN NABILAH ABD RAHIMIMAN NABILAH ABD RAHIM
IMAN NABILAH ABD RAHIM
TRThuhairah Hasrah Abdul Rahman
Thuhairah Hasrah Abdul Rahman
HNHapizah Mohd Nawawi
Hapizah Mohd Nawawi
Crocus sativus L. or saffron has been shown to have anti-atherogenic effects. However, its effects on key events in atherogenesis such as endothelial activation and monocyte-endothelial cell binding in lipolysaccharides (LPS)-stimulated in vitro model have not been extensively studied. Objectives: To investigate the effects of saffron and its bioactive derivative crocin on the gene and protein expressions of biomarkers of endothelial activation in LPS stimulated human coronary artery endothelial cells (HCAECs). Methodology: HCAECs were incubated with different concentrations of aqueous ethanolic extracts of saffron and crocin together with LPS. Protein and gene expressions of endothelial activation biomarkers were measured using ELISA and qRT-PCR, respectively. Adhesion of monocytes to HCAECs was detected by Rose Bengal staining. Methyl-thiazol-tetrazolium assay was carried out to assess cytotoxicity effects of saffron and crocin. Results: Saffron and crocin up to 25.0 and 1.6 μg/ml respectively exhibited >85% cell viability. Saffron treatment reduced sICAM-1, sVCAM-1 and E-selectin proteins (concentrations: 3.13, 6.25, 12.5 and 25.0 μg/ml; 3.13, 12.5 and 25.0 μg/ml; 12.5 and 25.0, respectively) and gene expressions (concentration: 12.5 and 25.0μg/ml; 3.13, 6.25 and 25.0 μg/ml; 6.25, 12.5 25.0; respectively). Similarly, treatment with crocin reduced protein expressions of sICAM-1, sVCAM-1 and E-selectin (concentration: 0.2, 0.4, 0.8 and 1.6 μg/ml; 0.4, 0.8 and 1.6 μg/ml; 0.8 and 1.6 μg/ml; respectively] and gene expression (concentration: 0.8 and 1.6 μg/ml; 0.4, 0.8 and 1.6 μg/ml; and 1.6 μg/ml, respectively). Monocyte-endothelial cell interactions were reduced following saffron treatment at concentrations 6.3, 12.5 and 25.00 μg/ml. Similarly, crocin also suppressed cellular interactions at concentrations 0.04, 0.08, 1.60 μg/ml. Conclusion: Saffron and crocin exhibits potent inhibitory action for endothelial activation and monocyte-endothelial cells interaction suggesting its potential anti-atherogenic properties.

23 September 2026 in BDJ Open
Verified
Journal Article
Open access
PDF file
IMAN NABILAH ABD RAHIMIMAN NABILAH ABD RAHIM
IMAN NABILAH ABD RAHIM
NONashuha Omar
Nashuha Omar
NZNorazreen Zakaria
Norazreen Zakaria
RZRahayu Zulkapli
Rahayu Zulkapli
RARohana Ahmad
Rohana Ahmad
Mohd Yusmiaidil Putera Mohd YusofMohd Yusmiaidil Putera Mohd Yusof
Mohd Yusmiaidil Putera Mohd Yusof
Background Artificial intelligence (AI) has rapidly expanded across dental research, particularly in imaging-based diagnostics and digital workflows. Despite the accelerating publication growth, the structural evolution, thematic maturity, and translational readiness of AI in dentistry remain insufficiently synthesised. Methods Publications related to AI in dentistry between 2015 and 2025 were retrieved from the Scopus database. Bibliometric analyses were conducted to examine annual outputs, countries, institutions, authors, journals, and keyword co-occurrence patterns. Network visualisation and clustering were performed using VOSviewer to identify research hotspots and thematic evolution. Selected evidence syntheses were evaluated using the Risk of Bias in Systematic Reviews (ROBIS) tool to assess methodological robustness and evidence maturity. Results A total of 3665 publications were included. Research output demonstrated marked post-2019 acceleration, with deep learning and convolutional neural networks dominating the methodological landscape. The United States, China, and India were the most productive countries, while a core group of highly connected authors shaped collaborative structures. Keyword clustering revealed a clear thematic progression from algorithmic development and image segmentation toward diagnostic imaging applications, digital dentistry integration, and workflow optimisation. Among the 75 systematic reviews evaluated using ROBIS, 50 (66.7%) demonstrated an unclear overall risk of bias, 24 (32.0%) showed a low risk of bias, and only one (1.3%) was classified as high risk, indicating that methodological transparency and evidence synthesis have not progressed at the same pace as technological innovation. Conclusion AI research in dentistry is experiencing rapid expansion and increasing international collaboration, and continuous thematic evolution towards clinically relevant applications. However, the ROBIS assessment indicates that improvements in methodological quality and reporting transparency of evidence syntheses are still required to strengthen confidence in the current evidence base. Future studies should prioritise multicentre validation, standardised evaluation frameworks, rigorous systematic reviews, and clinically meaningful outcome measures to facilitate the safe and effective translation of AI into routine dental practice.